Evofem Biosciences downgraded by Morgan Stanley with a new price target
$EVFM
Biotechnology: Pharmaceutical Preparations
Health Care
Morgan Stanley downgraded Evofem Biosciences from Equal-Weight to Underweight and set a new price target of $0.80
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/4/2022 | $0.50 → $0.53 | Underweight | Morgan Stanley |
| 11/16/2021 | $2.50 → $2.00 | Buy | HC Wainwright & Co. |
| 10/21/2021 | $4.00 → $2.50 | Buy | HC Wainwright & Co. |
| 10/14/2021 | $0.80 | Equal-Weight → Underweight | Morgan Stanley |
| 8/12/2021 | $3.00 → $1.00 | Equal-Weight | Morgan Stanley |
Morgan Stanley reiterated coverage of Evofem Biosciences with a rating of Underweight and set a new price target of $0.53 from $0.50 previously
HC Wainwright & Co. reiterated coverage of Evofem Biosciences with a rating of Buy and set a new price target of $2.00 from $2.50 previously
HC Wainwright & Co. reiterated coverage of Evofem Biosciences with a rating of Buy and set a new price target of $2.50 from $4.00 previously